clinical trial · NCT05144191
Insignia™ Hip Stem Outcomes Study
Stryker Orthopaedics·N/A·active not recruiting·n = 313
Hip OsteoarthritisAvascular NecrosisRheumatoid ArthritisPost-traumatic OsteoarthritisFemoral Neck FracturesTrochanteric FracturesSurgeryInsignia uncemented Hip Stem
brief summary
The objective of this study is to evaluate the safety and effectiveness of the Insignia™ Hip Stem for global market access and post-market clinical follow-up up to 10 years postoperative.
started
Feb 7, 2022
primary completion
Apr 2, 2034
completion
Apr 2, 2034
last updated
Jun 4, 2025
detailed description
This study is a prospective, post-market, multi-center clinical investigation of the Insignia™ Hip Stem for primary and revision total hip arthroplasty (THA) in a consecutive series of patients who meet the eligibility criteria. The total enrollment goal for the study is a minimum of 313 cases, all of which will receive the Insignia™ Hip Stem.
official title
Insignia™ Hip Stem Outcomes Study - A Prospective, Post-market, Multi-center Evaluation of the Clinical Outcomes of the Insignia™ Hip Stem for Total Hip Replacement Surgery
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol